In fact, several medical devices have suffered the same fate that Praluent faces. Jefferies analysts, for one, are so skeptical of a Sanofi/Regeneron victory that they’re discounting Praluent ...

The drug, called Praluent, from Sanofi and Regeneron Pharmaceuticals Inc., is considered the first major advance in cholesterol treatment since statins were first introduced more than 20 years ago.

To learn more about these conditions and how Praluent helps treat them, see the “What is Praluent used for?” section below. Praluent is given as an injection under your skin. Praluent contains ...

Praluent is a human monoclonal antibody targeting ... regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well ...

Compared with a statin alone, the addition of Praluent cost $308 000 per quality-adjusted life year (QALY) gained. But the addition of ezetimibe cost $81 000 per QALY compared with a statin alone.

Regeneron and Sanofi announced that both doses of Praluent (alirocumab) will be made available at a new US list price—60% lower than the original—in early March. Regeneron and Sanofi announced ...

Praluent is approved for use in addition to ... vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don't have many side effects, it is very expensive.My ...

I then started Praluent injections twice a month to control my cholesterol, which has been incredibly effective — maybe even too effective — and is the purpose of my writing to you.

The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to ...